Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5135385 | 0.93 | TSHR (0.40) | TSHRHSD11B1 | |
| SCHEMBL5135325 | 0.92 | TSHR (0.41) | TSHRHSD11B1 | |
| SCHEMBL5135696 | 0.91 | TSHR (0.40) | TSHRHSD11B1 | |
| SCHEMBL5072278 | 0.90 | TSHR (0.51) | TSHRALDH1A1HSD11B1 | |
| SCHEMBL5135082 | 0.90 | HSD11B1 (0.40) | TSHRHSD11B1 | |
| SCHEMBL5137395 | 0.90 | TSHR (0.42) | TSHRHSD11B1 | |
| SCHEMBL5136720 | 0.89 | TSHR (0.44) | TSHRALDH1A1HSD11B1 | |
| SCHEMBL5137696 | 0.89 | TSHR (0.41) | TSHRALDH1A1HSD11B1 | |
| SCHEMBL5135803 | 0.88 | NR1H2 (0.39) | TSHRHSD11B1 | |
| SCHEMBL5135509 | 0.88 | TSHR (0.38) | TSHRALDH1A1HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1490044-A4 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORP (US) | 2008-04-16 | — | — | EP | disclosed |
| EP-1490044-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003084524-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2003-10-16 | — | — | WO | disclosed |